Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology

Annals of Neurology

Volumn 78, Issue 2, 2015, Pages 160-177

  Drouin Ouellet, Janelle ^a   Sawiak, Stephen J ^b   Cisbani, Giulia ^c   Lagacé, Marie ^c   Kuan, Wei Li ^a   Saint Pierre, Martine ^c   Dury, Richard J ^d   Alata, Wael ^c   St Amour, Isabelle ^c   Mason, Sarah L ^a   Calon, Frédéric ^c,e   Lacroix, Steve ^c,e   Gowland, Penny A ^d   Francis, Susan T ^d   Barker, Roger A ^a   Cicchetti, Francesca ^c,e  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c University Laval   (Canada)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBUTROL; HUNTINGTIN; TIGHT JUNCTION PROTEIN; HTT PROTEIN, HUMAN; HUNTINGTON PROTEIN, MOUSE; NERVE PROTEIN; NUCLEAR PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL DENSITY; BLOOD VESSEL DIAMETER; BLOOD VESSEL PARAMETERS; BRAIN BLOOD VESSEL; BRAIN PERFUSION; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MALE; MIDDLE AGED; MOUSE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; ANIMAL; BLOOD VESSEL; BRAIN; BRAIN CIRCULATION; DISEASE MODEL; GENETICS; IMMUNOELECTRON MICROSCOPY; MAGNETIC RESONANCE ANGIOGRAPHY; METABOLISM; NEOSTRIATUM; ORGAN SIZE; PATHOLOGY; SCINTIGRAPHY; TRANSCYTOSIS; TRANSGENIC MOUSE; VASCULARIZATION;

ADULT; AGED; ANIMALS; BLOOD VESSELS; BLOOD-BRAIN BARRIER; BRAIN; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, TRANSGENIC; MICROSCOPY, IMMUNOELECTRON; MIDDLE AGED; NEOSTRIATUM; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; ORGAN SIZE; PERFUSION IMAGING; TIGHT JUNCTION PROTEINS; TRANSCYTOSIS;

EID: 84937730922     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24406     Document Type: Article

References (52)

1. Scherzinger E, Lurz R, Turmaine M, et al., Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997; 90: 549-558.
2. Arrasate M, Mitra S, Schweitzer ES, et al., Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004; 431: 805-810.
3. Muchowski PJ,. Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron 2002; 35: 9-12.
4. Cisbani G, Cicchetti F,. An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity. Cell Death Dis 2012; 3: e382.
5. Bradford J, Shin JY, Roberts M, et al., Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci U S A 2009; 106: 22480-22485.
6. Lee CY, Cantle JP, Yang XW,. Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis. FEBS J 2013; 280: 4382-4394.
7. Cicchetti F, Lacroix S, Cisbani G, et al., Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol 2014; 76: 31-42.
8. Weiss A, Trager U, Wild EJ, et al., Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. J Clin Invest 2012; 122: 3731-3736.
9. Kook SY, Hong HS, Moon M, et al., Abeta(1)(-)(4)(2)-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca(2)(+)-calcineurin signaling. J Neurosci 2012; 32: 8845-8854.
10. Zlokovic BV,. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011; 12: 723-738.
11. Cisbani G, Freeman TB, Soulet D, et al., Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability. Brain 2013; 136: 433-443.
12. Franciosi S, Ryu JK, Shim Y, et al., Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiol Dis 2012; 45: 438-449.
13. Lin CY, Hsu YH, Lin MH, et al., Neurovascular abnormalities in humans and mice with Huntington's disease. Exp Neurol 2013; 250: 20-30.
14. Harris GJ, Aylward EH, Peyser CE, et al., Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease. Arch Neurol 1996; 53: 316-324.
15. Harris GJ, Codori AM, Lewis RF, et al., Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999; 122: 1667-1678.
16. Hasselbalch SG, Oberg G, Sorensen SA, et al., Reduced regional cerebral blood flow in Huntington's disease studied by SPECT. J Neurol Neurosurg Psychiatry 1992; 55: 1018-1023.
17. Hayden MR, Hewitt J, Stoessl AJ, et al., The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease. Neurology 1987; 37: 1441-1447.
18. Penney JBJ, Vonsattel JP, MacDonald ME, et al., CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997; 41: 689-692.
19. Parker GJ, Roberts C, Macdonald A, et al., Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med 2006; 56: 993-1000.
20. Patlak CS, Blasberg RG, Fenstermacher JD,. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
21. Brookes MJ, Morris PG, Gowland PA, Francis ST,. Noninvasive measurement of arterial cerebral blood volume using Look-Locker EPI and arterial spin labeling. Magn Reson Med 2007; 58: 41-54.
22. Croal PL, Hall EL, Driver ID, et al., The effect of isocapnic hyperoxia on neurophysiology as measured with MRI and MEG. Neuroimage 2015; 105: 323-331.
23. Francis ST, Bowtell R, Gowland PA,. Modeling and optimization of Look-Locker spin labeling for measuring perfusion and transit time changes in activation studies taking into account arterial blood volume. Magn Reson Med 2008; 59: 316-325.
24. Vonsattel JP, Myers RH, Stevens TJ, et al., Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-577.
25. Vuono R, Winder-Rhodes S, de Sliva R, et al., The role of tau in the pathological process and clinical expression of Huntington's disease. Brain (in press).
26. Drouin-Ouellet J, St-Amour I, Saint-Pierre M, et al., Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease. Int J Neuropsychopharmacol 2014 Dec 7. pii: pyu103. doi: 10.1093/ijnp/pyu103. [Epub ahead of print].
27. Mangiarini L, Sathasivam K, Seller M, et al., Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
28. Alata W, Paris-Robidas S, Emond V, et al., Brain uptake of a fluorescent vector targeting the transferrin receptor: a novel application of in situ brain perfusion. Mol Pharm 2014; 11: 243-253.
29. Ouellet M, Emond V, Chen CT, et al., Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: an in situ cerebral perfusion study. Neurochem Int 2009; 55: 476-482.
30. Shetty R, Pibarot P, Audet A, et al., Lipid-mediated inflammation and degeneration of bioprosthetic heart valves. Eur J Clin Invest 2009; 39: 471-480.
31. Ben-Zvi A, Lacoste B, Kur E, et al., Mfsd2a is critical for the formation and function of the blood-brain barrier. Nature 2014; 509: 507-511.
32. Rizzo MT, Leaver HA,. Brain endothelial cell death: modes, signaling pathways, and relevance to neural development, homeostasis, and disease. Mol Neurobiol 2010; 42: 52-63.
33. Xu J, Chen S, Ku G, et al., Amyloid beta peptide-induced cerebral endothelial cell death involves mitochondrial dysfunction and caspase activation. J Cereb Blood Flow Metab 2001; 21: 702-710.
34. Jiao H, Wang Z, Liu Y, et al., Specific role of tight junction proteins claudin-5, occludin, and ZO-1 of the blood-brain barrier in a focal cerebral ischemic insult. J Mol Neurosci 2011; 44: 130-139.
35. Sengillo JD, Winkler EA, Walker CT, et al., Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease. Brain Pathol 2013; 23: 303-310.
36. Daneman R, Zhou L, Kebede AA, Barres BA,. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 2010; 468: 562-566.
37. Garrido-Urbani S, Bradfield PF, Lee BP, Imhof BA,. Vascular and epithelial junctions: a barrier for leucocyte migration. Biochem Soc Trans 2008; 36: 203-211.
38. Siegenthaler JA, Sohet F, Daneman R,. 'Sealing off the CNS': cellular and molecular regulation of blood-brain barriergenesis. Curr Opin Neurobiol 2013; 23: 1057-1064.
39. Tibbling G, Link H, Ohman S,. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 1977; 37: 385-390.
40. Black JE, Isaacs KR, Anderson BJ, et al., Learning causes synaptogenesis, whereas motor activity causes angiogenesis, in cerebellar cortex of adult rats. Proc Natl Acad Sci U S A 1990; 87: 5568-5572.
41. Lacoste B, Comin CH, Ben-Zvi A, et al., Sensory-related neural activity regulates the structure of vascular networks in the cerebral cortex. Neuron 2014; 83: 1117-1130.
42. Panov AV, Gutekunst CA, Leavitt BR, et al., Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 2002; 5: 731-736.
43. Zeron MM, Hansson O, Chen N, et al., Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002; 33: 849-860.
44. Carrano A, Hoozemans JJ, van der Vies SM, et al., Amyloid beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal 2011; 15: 1167-1178.
45. Cepeda-Prado E, Popp S, Khan U, et al., R6/2 Huntington's disease mice develop early and progressive abnormal brain metabolism and seizures. J Neurosci 2012; 32: 6456-6467.
46. Morita K, Sasaki H, Furuse M, Tsukita S,. Endothelial claudin: claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J Cell Biol 1999; 147: 185-194.
47. Nitta T, Hata M, Gotoh S, et al., Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 2003; 161: 653-660.
48. Quagliarello VJ, Ma A, Stukenbrok H, Palade GE,. Ultrastructural localization of albumin transport across the cerebral microvasculature during experimental meningitis in the rat. J Exp Med 1991; 174: 657-672.
49. Akiguchi I, Tomimoto H, Suenaga T, et al., Blood-brain barrier dysfunction in Binswanger's disease; an immunohistochemical study. Acta Neuropathol 1998; 95: 78-84.
50. Dallasta LM, Pisarov LA, Esplen JE, et al., Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am J Pathol 1999; 155: 1915-1927.
51. Bouchard J, Truong J, Bouchard K, et al., Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J Neurosci 2012; 32: 18259-18268.
52. Kwan W, Magnusson A, Chou A, et al., Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease. J Neurosci 2012; 32: 133-142.